[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555709":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":225,"collaborators":30,"id":227,"slug":30,"hasResults":228,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":30,"eligibilityCriteria":232,"healthyVolunteers":228,"sex":233,"minAge":234,"maxAge":30,"enrollmentInfo":235,"targetDuration":30,"studyType":238,"phases":239,"briefSummary":241,"conditions":242,"keywords":30,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},{"fullName":5,"class":6},"Context Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CTIM-76","EXPERIMENTAL","Phase 1a: Dose Escalation-each dose cohort will assess toxicity 28 days following the first dose of CTIM76; anticipate a total of 9 dose cohorts.\n\nPhase 1b: Dose Expansion - approximately 80 participants will be evaluated at a minimum of 2 dose levels and\u002For dosing schedules of CTIM-76",[13],"Drug: CTIM-76",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","CLDN6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28-day treatment cycle until disease progression.",[9],[20],"CTIM-76 Claudin 6 bispecific Antibody",[22],{"name":23,"affiliation":5,"role":24},"Karen Chagin, MD","STUDY_CHAIR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Context Clinical Development","CONTACT","267-225-7416",null,"cntx-ctim76-101@contexttherapeutics.com",[33,52,63,78,93,104,117,132,142,157,167,182,197,212],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"University of Arkansas Winthrop P. Rockefeller Cancer Institute","RECRUITING","Little Rock","Arkansas","72205","United States",{"type":41,"coordinates":42},"Point",[43,44],-92.28959,34.74648,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":50,"email":51},"Maroof Zafar","501-686-8274","24576","MKZafar@uams.edu",{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":39,"cosmosGeoPoint":58,"geoPoint":62,"contacts":30},"Precision NextGen Oncology & Research Center","WITHDRAWN","Beverly Hills","California","90212",{"type":41,"coordinates":59},[60,61],-118.40036,34.07362,{"lat":61,"lon":60},{"facility":64,"status":35,"city":65,"state":66,"zip":67,"country":39,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"SCRI at Denver Health","Denver","Colorado","80218",{"type":41,"coordinates":69},[70,71],-104.9847,39.73915,{"lat":71,"lon":70},[74],{"name":75,"role":28,"phone":76,"phoneExt":30,"email":77},"Front Desk","720-754-2610","CANN.DDUDenverGeneral@SarahCannon.com",{"facility":79,"status":35,"city":80,"state":81,"zip":82,"country":39,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":41,"coordinates":84},[85,86],-71.05977,42.35843,{"lat":86,"lon":85},[89],{"name":90,"role":28,"phone":91,"phoneExt":30,"email":92},"Rebecca Porter, MD","(877) 338-7425","Rebecca_Porter@DFCI.HARVARD.EDU",{"facility":94,"status":95,"city":96,"state":97,"zip":98,"country":39,"cosmosGeoPoint":99,"geoPoint":103,"contacts":30},"John Theurer Cancer Center","TERMINATED","Hackensack","New Jersey","07601",{"type":41,"coordinates":100},[101,102],-74.04347,40.88593,{"lat":102,"lon":101},{"facility":105,"status":35,"city":106,"state":106,"zip":107,"country":39,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Memorial Sloan Kettering Cancer Center","New York","10021",{"type":41,"coordinates":109},[110,111],-74.00597,40.71427,{"lat":111,"lon":110},[114],{"name":115,"role":28,"phone":30,"phoneExt":30,"email":116},"Roisin O'Cearbhaill, MD","ocearbhr@mskcc.org",{"facility":118,"status":35,"city":119,"state":120,"zip":121,"country":39,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Duke Cancer Institute","Durham","North Carolina","27710",{"type":41,"coordinates":123},[124,125],-78.89862,35.99403,{"lat":125,"lon":124},[128],{"name":129,"role":28,"phone":130,"phoneExt":30,"email":131},"Duke Cancer Institute - Phase I and Immunotherapy Trials","919-684-6342","Phase1andImmunotherapyreferrals@duke.edu",{"facility":133,"status":54,"city":134,"state":135,"zip":136,"country":39,"cosmosGeoPoint":137,"geoPoint":141,"contacts":30},"Gabrail Cancer Center","Canton","Ohio","44718",{"type":41,"coordinates":138},[139,140],-81.37845,40.79895,{"lat":140,"lon":139},{"facility":143,"status":35,"city":144,"state":145,"zip":146,"country":39,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Providence Cancer Institute of Oregon","Portland","Oregon","97213",{"type":41,"coordinates":148},[149,150],-122.67621,45.52345,{"lat":150,"lon":149},[153],{"name":154,"role":28,"phone":155,"phoneExt":30,"email":156},"Christopher Darus, MD","503-215-2075","CanRsrchStudies@Providence.org",{"facility":158,"status":54,"city":159,"state":160,"zip":161,"country":39,"cosmosGeoPoint":162,"geoPoint":166,"contacts":30},"Fox Chase Cancer Center","Philadelphia","Pennsylvania","19111",{"type":41,"coordinates":163},[164,165],-75.16362,39.95238,{"lat":165,"lon":164},{"facility":168,"status":35,"city":169,"state":170,"zip":171,"country":39,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Women & Infants Hospital of Rhode Island","Providence","Rhode Island","02905",{"type":41,"coordinates":173},[174,175],-71.41283,41.82399,{"lat":175,"lon":174},[178],{"name":179,"role":28,"phone":180,"phoneExt":30,"email":181},"Mary Dionne","401-453-8181","MDionne@WIHRI.org",{"facility":183,"status":35,"city":184,"state":185,"zip":186,"country":39,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Vanderbilt-Ingram Cancer Center","Nashville","Tennessee","37232",{"type":41,"coordinates":188},[189,190],-86.78444,36.16589,{"lat":190,"lon":189},[193],{"name":194,"role":28,"phone":195,"phoneExt":30,"email":196},"Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)","800-811-8480","CTIP@VUMC.ORG",{"facility":198,"status":35,"city":199,"state":200,"zip":201,"country":39,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"SCRI at Mary Crowley","Dallas","Texas","75230",{"type":41,"coordinates":203},[204,205],-96.80667,32.78306,{"lat":205,"lon":204},[208],{"name":209,"role":28,"phone":210,"phoneExt":30,"email":211},"Angela Hotchkiss","214-658-1958","ahotchkiss@marycrowley.org",{"facility":213,"status":35,"city":214,"state":30,"zip":30,"country":215,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"University College London Hospital","London","United Kingdom",{"type":41,"coordinates":217},[218,219],-0.12574,51.50853,{"lat":219,"lon":218},[222],{"name":223,"role":28,"phone":30,"phoneExt":30,"email":224},"UCLH Referrals","uclh.referrals.clinicalresearchfacility@nhs.net",{"type":226,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100555709",false,"NCT06515613","A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors","A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors","Inclusion Criteria:\n\n* Participants with CLDN6 positive platinum resistant\u002Frefractory ovarian, advanced testicular or advanced endometrial cancer.\n* Participants with measurable disease per RECIST 1.1.\n* ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.\n* Participants with adequate organ function.\n\nExclusion Criteria:\n\n* Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.\n* Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.\n* Concurrent participation in another investigational clinical trial.","ALL","18 Years",{"count":236,"type":237},156,"ESTIMATED","INTERVENTIONAL",[240],"PHASE1","This is a Phase 1a\u002F1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory\u002Fresistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).",[243,244,245],"Platinum-resistant Ovarian Cancer","Testicular Cancer","Endometrial Cancer","2026-06-15",{"date":248,"type":249},"2026-06-16","ACTUAL",{"date":251,"type":249},"2024-07-10",{"date":253,"type":237},"2028-12-31",{"name":5,"class":6},14]